

Human Microbiome-based Drugs and Diagnostics: Global Markets

<https://marketpublishers.com/r/H055957E6F2EN.html>

Date: May 2017

Pages: 124

Price: US\$ 2,750.00 (Single User License)

ID: H055957E6F2EN

Abstracts

The global market for human microbiome-based drugs and diagnostics should reach a market size of nearly \$9.9 billion by 2024.

The human microbiome-based drugs constitute 95% of this market and should reach \$9.3 billion in sales by 2024.

The size of the microbiome diagnostics market is expected to remain modest at \$543.8 million in 2024.

Contents

CHAPTER 1 INTRODUCTION

Study Goals and Objectives
Reasons for Doing This Study
Intended Audience
Scope of Report
Information Sources
Methodology
Geographic Breakdown
Analyst's Credentials
Related BCC Research Reports

CHAPTER 2 SUMMARY AND HIGHLIGHTS

CHAPTER 3 MICROBIOME OVERVIEW

Scientific Background
Human Microbiome in Health and Disease
Advances in Microbiome Research
Focus Areas for Microbiome-Based Drugs and Diagnostics
Microbiome-Based Drugs: Product Development Strategies
Current Challenges in Microbiome Drug Development
Human Microbiome Project
MetaHIT Consortium
Public Sector Initiatives in Microbiome Research
Key Goals of the Human Microbiome Project
Key Achievements of the Human Microbiome Project
Key Goals of MetaHIT Initiative

CHAPTER 4 HUMAN MICROBIOME-BASED DRUGS MARKET

Cancer
Obesity
Type 2 Diabetes
Ulcerative Colitis and Crohn's Disease
Clostridium Difficile Infection
Lactose Intolerance

Dental caries

Recurrent Bacterial Vaginosis and Urinary Tract Infection

Skin Diseases

Hyperoxaluria

Urea Cycle Disorder

Celiac Disease

Phenylketonuria

Non-alcoholic Steatohepatitis (NASH)

Background

Microbiome and Cancer

Microbiome-based Drugs for Cancer: Review of Drugs in Development

Market for Microbiome-based Drugs for Cancer

Background

Microbiome and Obesity

Microbiome-based Drugs for Obesity: Review of Drugs in Development

Market for Microbiome-based Drugs for Obesity

Background

Microbiome and Type 2 Diabetes

Microbiome-based Drugs in Type 2 Diabetes: Review of Drugs in Development

Market for Microbiome-based Drugs for Type 2 Diabetes

Background

Microbiome and Ulcerative Colitis/Crohn's Disease

Microbiome-based Drugs for Ulcerative Colitis and Crohn's Disease: Review of Drugs in Development

Market for Microbiome-Based Products for Ulcerative Colitis and Crohn's Disease

Background

Microbiome and Clostridium Difficile Infection

Microbiome-based Drugs for Clostridium Difficile Infection: Review of Drugs in Development

Market for Microbiome-based Drugs for Clostridium Difficile Infection

Background

Microbiome and Lactose Intolerance

Microbiome-based Drugs for Lactose Intolerance: Review of Drugs in Development

Market for Microbiome-based Product for Lactose Intolerance

Background

Microbiome and Dental Caries

Microbiome-based Drugs for Dental Caries Review of Drugs in Development

Market for Microbiome-based Products for Dental Caries

Background

Microbiome and Recurrent Bacterial Vaginosis and Urinary Tract Infection
Microbiome-based Drugs for Recurrent Bacterial Vaginosis and Urinary Tract Infection:
Drugs in Development
Market for Microbiome-based Products for Recurrent Bacterial Vaginosis and UTI
Background
Microbiome and Skin Diseases
Microbiome-based Drugs for Skin Diseases: Review of Drugs in Development
Market for Microbiome-based Drugs for Skin Diseases
Background
Microbiome and Hyperoxaluria
Microbiome-based Drugs for Hyperoxaluria: Review of Drugs in Development
Market for Microbiome-based Products for Hyperoxaluria
Background
Microbiome and Urea Cycle Disorder
Microbiome-based Drugs for Urea Cycle Disorder: Review of Drugs in Development
Market for Microbiome-Based Drugs for Urea Cycle Disorder
Background
Microbiome and Celiac Disease
Microbiome-Based Drugs for Celiac Disease: Review of Drugs in Development
Market for Microbiome-based Products for Celiac Disease
Background
Microbiome and Phenylketonuria
Microbiome-based Drugs for Phenylketonuria: Review of Drugs in Development
Market for Microbiome-based Products for Phenylketonuria
Background
Microbiome and Non-alcoholic Steatohepatitis
Microbiome-based Drugs for Non-alcoholic Steatohepatitis: Review of Drugs in
Development
Market for Microbiome-based Products for Non-alcoholic Steatohepatitis
Microbiome-based Products for Hepatic Encephalopathy
Microbiome and Hepatic Encephalopathy
Microbiome-based Drugs for Hepatic Encephalopathy: Review of Drugs in Development
Market for Microbiome-based Drugs for Hepatic Encephalopathy
Drug Development Strategies
Microbiome-Based Drugs as Immune System Activators
Microbiome-Based Drugs as an Add-on to Immuno-Oncology Drugs
Microbiome-Based Drugs as Probiotic Mixtures
Microbiome-Based Drugs as Chemotherapy Adjuncts
Microbiome-Based Drugs in Development for Cancer

Micabodies (AvidBiotics)
Oncobiotics (Evelo Biosciences)
SER-155 (Seres Therapeutics)
Symberix Compound (Symberix)
MRX581 (4D Pharma)
AG-013 (Intrexon)
Microbial Mechanism of Disease in Obesity
Microbiota Associated with Obesity
Drug Development Strategies
Drugs in Development for Obesity
NM-504 (Microbiome Therapeutics)
NM-313 (Microbiome Therapeutics)
Fecal Microbiota Transplant (Seres Therapeutics)
Drug Development Strategies
Drugs in Development
NM-504 (Microbiome Therapeutics)
Bovin Colostrum (Immuron)
CP-001 (Caelus Health)
Seres Diabetes Program (Seres Therapeutics)
Microbiota Associated with Ulcerative Colitis and Crohn's Disease
Drugs in Development
EB-80818 (Enterome Biosciences)
EB-110 (Enterome Biosciences)
EB-120 (Enterome Biosciences)
SER-287 (Seres Therapeutics)
SGM-019 (Second Genome)
VT-301 (ViThera Pharmaceuticals)
RBX-8225 (Rebiotix)
AG-014 (Intrexon)
Market for Microbiome-based Drugs for Ulcerative Colitis
Market for Microbiome-Based Drugs for Crohn's Disease
Drug Development Strategies
Drugs in Development
VE-202 (Vedanta Biosciences)
SYN-004 (Synthetic Biologics)
SER-262/SER-109 (Seres Therapeutics)
Avidocin Proteins (AvidBiotics)
DAV-132 (DA Volterra)
CBM-588 (Osel Inc.)

RBX-2660 (Rebiotix)
Drug Development Strategies
Drugs in Development
RP-G28 (Ritter Pharmaceuticals)
Drug Development Strategies
Drugs in Development
C16-G2 (C3 Jian Inc.)
Drug Development Strategies
Drugs in Development
Acne
Rosacea
Atopic Dermatitis
Acne
Atopic Dermatitis
Rosacea
Drug Development Strategies
Drugs in Development
B-244 (AOBiome)
Drug Development Strategies
Drugs in Development
Drug Development Strategies
Drugs in Development
Drug Development Strategies
Drugs in Development
Drug Development Strategies
Drugs in Development
Drug Development Strategies
Drugs in Development
Background
Drug Development Strategies
Drugs in Development

CHAPTER 5 HUMAN MICROBIOME-BASED DIAGNOSTICS MARKET

Microbiome Diagnostics: Overview
Microbiome Diagnostics: Technologies
Microbiome Diagnostics: Applications
Microbiome Diagnostics: Industry Collaborations
Market for Microbiome Diagnostics

Microbiome-based Diagnostics for Ulcerative Colitis and Crohn's Disease

Microbiome-based Diagnostics for Cancer

Microbiome Diagnostics for Women's Health

Microbiome Diagnostics for Dental caries

Overview

Companion Diagnostics in Development

IBD-210

IBD-110

Market for Microbiome-based Diagnostics for Ulcerative Colitis and Crohn's Disease

Overview

Companion Diagnostics in Development

Oricol

Market for Microbiome-based Diagnostics for Cancer

Overview

Market for Microbiome Diagnostics for Women's Health

Overview

Microbiome-based Diagnostics in Development

Market for Microbiome-based Diagnostic for Dental Caries

CHAPTER 6 MICROBIOME INTELLECTUAL PROPERTY, INVESTMENTS AND COLLABORATIONS

Intellectual Property

Investments and Collaborations

Overview

Microbiome Patent Segments

Patents by Disease Area

Investments: Overview

Public Sector Investments

Private Sector Investments

Collaborations: overview

Microbiome Public Databases Overview

Clostridium Difficile Infection

Irritable Bowel Disorders

Diabetes and Obesity

Cancer

Lactose Intolerance

Hyperoxaluria

Recurrent Bacterial Vaginosis and Urinary tract infection

Dental Caries
Urea Cycle Disorders
Human Microbiome Initiative
MetaHIT Initiative
Venture Capital Investments
Initial Public Offerings
Industry Collaborations
Vedanta Biosciences/Johnson & Johnson
Seres Therapeutics/Nestle Health Science
Enterome Biosciences/Bristol-Meyers Squibb Co. (BMS)
Enterome Biosciences/Abbvie
Enterome Biosciences/Takeda
Synlogic Inc./AbbVie
Second Genome/Johnson & Johnson
Second Genome/Pfizer
Industry/Academic Collaborations
Enterome Biosciences/Mayo Clinic
Janssen Microbiome Institute/DayTwo Ltd. and Weizmann Institute
Vedanta Biosciences/NYU Langone Medical Center
Seres Therapeutics/Massachusetts General Hospital (MGH)
Seres Therapeutics/Mayo Clinic
Seres Therapeutics/University of Pennsylvania
Second Genome/The American Gut Project
Second Genome/King's College, London
Whole Biome/Mayo Clinic
American Gut Project Database
Integrative Human Microbiome Project Database
Human Oral Microbiome Database

CHAPTER 7 COMPANY PROFILES

4D PHARMA
AVIDBIOTICS INC.
AOBIOME LLC
AXIAL BIOTHERAPEUTICS
C3 JIAN INC.
CAELUS HEALTH
DA VOLTERRA
ELIGO BIOSCIENCES

ENTEROME BIOSCIENCES
EVELO BIOSCIENCES
EVOLVE BIOSYSTEMS
METABIOMICS
MICROBIOME THERAPEUTICS
ORIGIN SCIENCES LTD.
OSEL INC.
OXTHERA
RITTER PHARMACEUTICALS
REBIOTIX INC.
SECOND GENOME
SERES THERAPEUTICS
SYMBERIX
SYNLOGIC BIOTICS
SYNTHETIC BIOLOGICS
UBIOME INC.
VEDANTA BIOSCIENCES
VITHERA PHARMACEUTICALS
4D PHARMA PIPELINE
AvidBiotics Pipeline
Aobiome pipeline
C3 jian pipeline
Caelus Health Pipeline
Da Volterra Pipeline
Enterome Pipeline
Microbiome Therapeutics Pipeline
Osel Pipeline
Oxthera Pipeline
Ritter Pharmaceuticals Pipeline
Rebiotix Pipeline
Second Genome Pipeline
Seres Therapeutics Pipeline
Symberix Pipeline
Synlogic Pipeline
Synthetic Biologics Pipeline
Vedanta Biosciences Pipeline
ViThera Pharmaceuticals Pipeline

List Of Tables

LIST OF TABLES

Table 1 Summary Table: Global Market for Human Microbiome Based Drugs by Disease Indication, through 2024

Table 2 Focus Disease Areas for Microbiome Research

Table 3 Microbiome Drug Development Approaches

Table 4 U.S. Prevalence of Cancer, through 2024

Table 5 Microbiota Associated with Cancers

Table 6 Microbiome-based Drugs in Development for Cancer

Table 7 U.S. Market Shares of Microbiome-based Drugs for Cancer, by Company, 2018-2024

Table 8 U.S. Patient Volumes for Microbiome-based Drugs for Cancer, by Company, through 2024

Table 9 U.S. Market for Microbiome-based Drugs for Cancer, by Company, through 2024

Table 10 Rest of the World Market for Microbiome-based Drugs for Cancer, by Country/Region, through 2024

Table 11 U.S. Prevalence of Obesity, through 2024

Table 12 Microbiota Associated with Obesity

Table 13 Microbiome-based Drugs in Development for Obesity

Table 14 U.S. Market Shares of Microbiome-based Drugs for Obesity, by Company, 2018-2024

Table 15 U.S. Patient Volumes for Microbiome-based Drugs for Obesity, by Company, through 2024

Table 16 U.S. Market for Microbiome-based Drugs for Obesity, by Company, through 2024

Table 17 U.S. Prevalence of Type 2 Diabetes, through 2024

Table 18 Microbiota Associated with Type 2 Diabetes

Table 19 Microbiome-based Drugs in Development for Type 2 Diabetes

Table 20 U.S. Market Shares of Microbiome-based Drugs for Type 2 Diabetes, by Company, 2018-2024

Table 21 U.S. Patient Volumes for Microbiome-based Drugs for Type 2 Diabetes, by Company, through 2024

Table 22 U.S. Market for Microbiome-based Drugs for Type 2 Diabetes, by Company, through 2024

Table 23 Rest of the World Market for Microbiome-based Drugs for type 2 Diabetes, by Country/Region, through 2024

Table 24 U.S. Prevalence of Ulcerative Colitis and Crohn's Disease, through 2024

Table 25 Microbiome-based Drugs in Development for Ulcerative Colitis and Crohn's Disease

Table 26 U.S. Market for Microbiome-based Drugs for Ulcerative Colitis and Crohn's Disease, through 2024

Table 27 Rest of the World Market for Microbiome-based Drugs for Ulcerative Colitis and Crohn's Disease, through 2024

Table 28 U.S. Market Shares of Microbiome-based Drugs for Ulcerative Colitis, by Company, 2018-2024

Table 29 U.S. Patient Volumes for Microbiome-based Drugs for Ulcerative Colitis, by Company, through 2024

Table 30 U.S. Market for Microbiome-based Drugs for Ulcerative Colitis, by Company, through 2024

Table 31 Rest of the World Market for Microbiome-based Drugs for Ulcerative Colitis, by Country/Region, through 2024

Table 32 U.S. Market Shares of Microbiome-based Drugs for Crohn's Disease, by Company, 2018-2024

Table 33 U.S. Patient Volumes for Microbiome-based Drugs for Crohn's Disease, by Company, through 2024

Table 34 U.S. Market for Microbiome-based Drugs for Crohn's Disease, by Company, through 2024

Table 35 Rest of the World Market for Microbiome-based Drugs for Crohn's Disease, by Country/Region, through 2024

Table 36 U.S. Prevalence of Clostridium Difficile Infection, through 2024

Table 37 Microbiome-based Drugs in Development for Clostridium Difficile Infection

Table 38 U.S. Market Shares of Microbiome-based Drugs for Clostridium Difficile Infection, by Company, 2018-2024

Table 39 U.S. Patient Volumes for Microbiome-based Drugs for Clostridium Difficile Infection, by Company, through 2024

Table 40 U.S. Market for Microbiome-based Drugs for Clostridium Difficile Infection, by Company, through 2024

Table 41 Rest of the World Market for Microbiome-based Drugs for Clostridium Difficile Infection, by Country/Region, through 2024

Table 42 U.S. Prevalence of Lactose Intolerance, through 2024

Table 43 Microbiome-based Drugs in Development for Clostridium Difficile Infection

Table 44 U.S. Market Shares of Microbiome-based Drugs for Lactose Intolerance, by Company, 2018-2024

Table 45 U.S. Patient Volumes for Microbiome-based Drugs for Lactose Intolerance, by Company, through 2024

Table 46 U.S. Market for Microbiome-based Drugs for Lactose Intolerance, by Company, through 2024

Table 47 Rest of the World Market for Microbiome-based Drugs for Lactose Intolerance, by Country/Region, through 2024

Table 48 U.S. Prevalence of Dental Caries, through 2024

Table 49 Microbiome-based Drugs in Development for Clostridium Difficile Infection

Table 50 U.S. Market Shares of Microbiome-based Drugs for Dental Caries, by Company, 2018-2024

Table 51 U.S. Patient Volumes for Microbiome-based Drugs for Dental Caries, by Company, through 2024

Table 52 U.S. Market for Microbiome-based Drugs for Dental Caries, by Company, through 2024

Table 53 Rest of the World Market for Microbiome-based Drugs for Dental Caries, by Country/Region, through 2024

Table 54 U.S. Prevalence of Recurrent Bacterial Vaginosis and Urinary Tract Infection, through 2024

Table 55 Microbiome-based Drugs in Development for Recurrent Bacterial Vaginosis and Urinary Tract Infection

Table 56 U.S. Market Shares of Microbiome-based Drugs for Recurrent Bacterial Vaginosis and Urinary Tract Infection, by Company, 2018-2024

Table 57 U.S. Patient Volumes for Microbiome-based Drugs for Recurrent Bacterial Vaginosis and Urinary Tract Infection, by Company, through 2024

Table 58 U.S. Market for Microbiome-based Drugs for Recurrent Bacterial Vaginosis and Urinary Tract Infection, by Company, through 2024

Table 59 Rest of the World Market for Microbiome-based Drugs for Recurrent Bacterial Vaginosis and Urinary Tract Infection, by Country/Region, through 2024

Table 60 U.S. Prevalence of Skin Diseases, through 2024

Table 61 Microbiome-based Drugs in Development for Skin Diseases

Table 62 U.S. Market Shares of Microbiome-based Drugs for Skin Diseases, by Company, 2018-2024

Table 63 U.S. Patient Volumes for Microbiome-Based Drugs for Skin Diseases, by Company, through 2024

Table 64 U.S. Market for Microbiome-based Drugs for Skin Diseases, by Company, through 2024

Table 65 Rest of the World Market for Microbiome-based Drugs for Skin Diseases, by Country/Region, through 2024

Table 66 U.S. Prevalence of Hyperoxaluria, through 2024

Table 67 Microbiome-based Drugs in Development for Skin Diseases

Table 68 U.S. Market Shares of Microbiome-based Drugs for Hyperoxaluria, by

Company, 2018-2024

Table 69 U.S. Patient Volumes for Microbiome-based Drugs for Hyperoxaluria, by Company, through 2024

Table 70 U.S. Market for Microbiome-based Drugs for Hyperoxaluria, by Company, through 2024

Table 71 Rest of the World Market for Microbiome-based Drugs for Hyperoxaluria, by Country/Region, through 2024

Table 72 U.S. Prevalence of Urea Cycle Disorder, through 2024

Table 73 Microbiome-based Drugs in Development for Urea Cycle Disorder

Table 74 U.S. Market Shares of Microbiome-based Drugs for Urea Cycle Disorder, by Company, 2018-2024

Table 75 U.S. Patient Volumes for Microbiome-based Drugs for Urea Cycle Disorder, by Company, through 2024

Table 76 U.S. Market for Microbiome-based Drugs for Urea Cycle Disorder, by Company, through 2024

Table 77 U.S. Prevalence of Celiac Disease, through 2024

Table 78 Microbiota Associated with Celiac Disease

Table 79 Microbiome-based Drugs in Development for Celiac Disease

Table 80 U.S. Market Shares of Microbiome-based Drugs for Celiac Disease, by Company, 2018-2024

Table 81 U.S. Patient Volumes for Microbiome-based Drugs for Celiac Disease, by Company, through 2024

Table 82 U.S. Market for Microbiome-based Drugs for Celiac Diseases, by Company, through 2024

Table 83 U.S. Prevalence of Phenylketonuria, through 2024

Table 84 U.S. Market Shares of Microbiome-based Drugs for Phenylketonuria, by Company, 2018-2024

Table 85 U.S. Market Shares of Microbiome-based Drugs for Phenylketonuria, by Company, 2018-2024

Table 86 U.S. Patient Volumes for Microbiome-based Drugs for Phenylketonuria, by Company, through 2024

Table 87 U.S. Market for Microbiome-based Drugs for Phenylketonuria, by Company, through 2024

Table 88 Rest of the World Market for Microbiome-based Drugs for Celiac Diseases, by Country/Region, through 2024

Table 89 U.S. Prevalence of Non-alcoholic Steatohepatitis, through 2024

Table 90 Microbiome-based Drugs in Development for Non-alcoholic Steatohepatitis

Table 91 U.S. Market Shares of Microbiome-based Drugs for Non-alcoholic Steatohepatitis, by Company, 2018-2024

Table 92 U.S. Patient Volumes for Microbiome-based Drugs for Non-alcoholic Steatohepatitis, by Company, through 2024

Table 93 U.S. Market for Microbiome-based Drugs for Non-alcoholic Steatohepatitis, by Company, through 2024

Table 94 Rest of the World Market for Microbiome-based Drugs for Non-alcoholic Steatohepatitis, by Country/Region, through 2024

Table 95 U.S. Prevalence of Hepatic Encephalopathy, through 2024

Table 96 Microbiome-based Drugs in Development for Hepatic Encephalopathy

Table 97 U.S. Market Shares of Microbiome-based Drugs for Hepatic Encephalopathy, by Company, 2018-2024

Table 98 U.S. Patient Volumes for Microbiome-based Drugs for Hepatic Encephalopathy, by Company, through 2024

Table 99 U.S. Market for Microbiome-based Drugs for Hepatic Encephalopathy, by Company, through 2024

Table 100 Rest of the World Market for Microbiome-based Drugs for Hepatic Encephalopathy, by Country/Region, through 2024

Table 101 Comparison of Microbiome Sequencing Technologies

Table 102 U.S. Market for Microbiome-based Diagnostics, by Disease Segment, through 2024

Table 103 Rest of the World Market for Microbiome-based Diagnostics, by Country/Region, through 2024

Table 104 U.S. Market Shares of Microbiome-based Diagnostics for Ulcerative Colitis and Crohn's Disease, 2018-2024

Table 105 U.S. Assay Volumes for Microbiome-based Diagnostics for Ulcerative Colitis and Crohn's Disease, through 2024

Table 106 U.S. Market for Microbiome-based Diagnostics for Ulcerative Colitis and Crohn's Disease, through 2024

Table 107 U.S. Prevalence of Microbiome-based Diagnostics for Colorectal Cancer, through 2024

Table 108 U.S. Market Shares of Microbiome-based Diagnostics for Colorectal Cancer, by Company, 2018-2024

Table 109 U.S. Assay Volumes for Microbiome-based Diagnostics for Colorectal Cancer, through 2024

Table 110 U.S. Market for Microbiome-based Diagnostics for Colorectal Cancer, through 2024

Table 111 U.S. Prevalence of Microbiome-based Diagnostics for Women's Health, through 2024

Table 112 U.S. Market Shares of Microbiome-based Diagnostics for Women's Health, by Company, 2018-2024

Table 113 U.S. Assay Volumes for Microbiome-based Diagnostics for Women's Health, through 2024

Table 114 U.S. Market for Microbiome-based Diagnostics for Women's Health, through 2024

Table 115 U.S. Market Shares of Microbiome-based Diagnostics for Dental Caries, by Company, 2018-2024

Table 116 U.S. Assay Volumes for Microbiome-based Diagnostics for Dental Caries, through 2024

Table 117 U.S. Market for Microbiome-based Diagnostics for Dental Caries, by Company through 2024

Table 118 U.S. Patents and Patent Applications on Microbiome-based Drugs for C. Difficile Infection

Table 119 U.S. Patents and Patent Applications on Microbiome-based Drugs for Irritable Bowel Syndrome

Table 120 U.S. Patents and Patent Applications on Microbiome-based Drugs for Diabetes and Obesity

Table 121 U.S. Patents and Patent Applications on Microbiome-based Drugs for Cancer

Table 122 U.S. Patents and Patent Applications on Microbiome-based Drugs for Lactose Intolerance

Table 123 U.S. Patents and Patent Applications on Microbiome-based Drugs for Hyperxaluria

Table 124 U.S. Patents and Patent Applications on Microbiome-based Drugs for Recurrent Bacterial Vaginosis and Urinary Tract Infection

Table 125 U.S. Patents and Patent Applications on Microbiome-Based Drugs for Dental Caries

Table 126 U.S. Patents and Patent Applications on Microbiome-based Drugs for Urea Cycle Disorders

Table 127 Venture Capital Investments in Microbiome Start-Ups

Table 128 Initial Public Offerings by Microbiome-Based Companies

Table 129 Industry collaborations in Microbiome-based Companies

Table 130 4D Pharma Pipeline

Table 131 Avidbiotics Pipeline

Table 132 AObiome Pipeline

Table 133 C3 Jian Pipeline

Table 134 Caelus Pipeline

Table 135 Da Volterra Pipeline

Table 136 Enterome Pipeline

Table 137 Microbiome Therapeutics Pipeline

Table 138 Osel Pipeline

Table 139 Oxthera Pipeline
Table 140 Oxthera Pipeline
Table 141 Rebiotix Pipeline
Table 142 Second Genome Pipeline
Table 143 Seres Therapeutics Pipeline
Table 144 Synlogic Pipeline
Table 145 Synthetic Biologics Pipeline
Table 146 Vedanta Biosciences Pipeline
Table 147 ViThera Pharmaceuticals Pipeline

List Of Figures

LIST OF FIGURES

Figure 1 Summary Figure A: Global Market for Human Microbiome Based Drugs and Diagnostics, 2018-2024

Figure 2 Summary Figure B: Global Market for Human Microbiome Based Drugs by Region, 2018-2024

Figure 3 Summary Figure C: Global Market for Human Microbiome Based Diagnostics by Region, 2018-2024

Figure 4 Human Microbiome Based Drugs, Pipeline Projects, 2016

Figure 5 Microbes Involved in Healthy Facial Skin

Figure 6 Number of Patents Granted for Worldwide Microbiome-based Drugs, 2002-2016

I would like to order

Product name: Human Microbiome-based Drugs and Diagnostics: Global Markets

Product link: <https://marketpublishers.com/r/H055957E6F2EN.html>

Price: US\$ 2,750.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/H055957E6F2EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970